Overview

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine the maximum tolerated and efficient dose of GRASPA® in combination with polychemotherapy treatment of elderly patients with ALL, 55 years and over, Philadelphia chromosome-negative (ALL Ph-).

Phase:

Phase 2

Details

Lead Sponsor:

ERYtech Pharma

Treatments:

Asparaginase